ArticleLeukemia2025

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.

Ian M Bouligny et al.PubMed ↗Publisher ↗

No numbers read from the abstract.